Meningococcal meningitis, a rarely occurring bacterial disease, holds the potential of affecting the brain. Despite the medical sector following a positive growth trail, the disease can eliminate the host within a comparatively shorter time period. Studies find that one in ten meningococcal meningitis cases end in mortality, while about 15% of the survivors suffer from fatal complications, including brain damage, deafness, or amputation. Uncertain spreading of the bacteria, accompanied by erratic occurrences across diverse age cohorts, and topologies are driving the count of clinical experiments for developing effective meningococcal vaccines globally.
Intensifying prominence of various types of bacteria leading to meningococcal meningitis, with A, B, C, W, Y, and type X being the most common, persist to underpin the demand for more efficient meningococcal vaccines in the upcoming years. On a worldwide scale, about 30 clinical trials for meningococcal vaccines are being performed at various phases of development. Although there is no vaccine capable of countering all sorts of meningitis, expansion of high-potential vaccines has witnessed substantial progress in recent years.
The world is observing reduction in bacterial meningitis cases by a fourth, with majority of the declination attributed to the increasing employment of vaccination. Recognizing the growing adoption of vaccination against meningococcal, Persistence Market Research, in its new business intelligence report, finds that the meningococcal vaccine market pegged ~US$ 2,228 Mn in 2018. Further, the report expects that the meningococcal vaccine market is envisioned to progress at a healthy of ~10% over the forecast period.
Healthcare Organizations Highly Recommend Meningococcal Conjugate Vaccines for Routine Dosages
Conjugate vaccines offer numerous benefits over their polysaccharide counterparts – better antibody continuity, avidity, immunologic memory, and herd immunity. Conjugate vaccines provide prolonged immunity by converting the T-cell independent immune response to a T-cell dependent one.
Quadrivalent conjugate vaccines for meningitis, for instance Menactra and Menveo, shield against four types of meningococcal bacteria, including type A, C, W, and Y. The Centers for Disease Control and Prevention (CDC) advises regular meningococcal conjugate vaccination for infants, and individuals aging 11-12 years. The protection from conjugate vaccines diminishes within 5 years post first dosages, requiring the need for a booster dose at the age of 16 years.
Meningitis and meningococcal diseases affect all over the globe, with sub-Saharan Africa – the meningitis belt – witnessing largest number of cases of meningococcal disease. Individuals intending to visit Saudi Arabia for hajj or umrah are supposed to possess evidence of the quadrivalent (serogroup A, C, W, or Y) vaccination. In addition, patients are directed to get the conjugate vaccines (MCV-4), Menactra and Menveo, within 8 years prior arrival.
Request For Report Sample: https://www.persistencemarketresearch.com/samples/3640
Market Players Leverage North America Citing Upsurge in Awareness Programs
According to a study by the U.S. Habitats for Disease Control and Prevention (CDC), about 350 cases of meningococcal infection were recorded in the US in 2017. With the government organizing awareness campaigns regarding the disease, the country is witnessing significant decline in the rate of meningococcal disease since the past three decades. Non-profit organizations in the US are providing insights, and medical aid to individuals affected by meningitis. Furthermore, multitude of programs are being organized to spread the word in public and the medical settings regarding the initial symptoms of meningitis.